SCHEMBL1697369

SCHEMBL1697369

CC(=O)NC(CO)C(=O)NCc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.74
CA1 P00915 1/20 0.74
CA2 P00918 1/20 0.74
CA3 P07451 1/20 0.74
CA4 P22748 1/20 0.74
CA6 P23280 1/20 0.74
CA5A P35218 1/20 0.74
CA7 P43166 1/20 0.74
CACNA1C Q13936 1/20 0.74
SCN9A Q15858 1/20 0.74
CA9 Q16790 1/20 0.74
CA13 Q8N1Q1 1/20 0.74
CA14 Q9ULX7 1/20 0.74
CA5B Q9Y2D0 1/20 0.74
ALDH1A1 P00352 1/20 0.63
MMP8 P22894 3/20 0.62
CTSS P25774 1/20 0.57
CTSK P43235 1/20 0.57
EGFR P00533 1/20 0.56
SRC P12931 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8205298 1.00 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL47275 1.00 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL1895974 0.88 CA1 (0.70) CA12CA1CA2CA3CA4
SCHEMBL12240240 0.88 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL2742289 0.88 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL2606494 0.88 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL12840933 0.87 CA12 (0.62) CA12CA1CA2CA3CA4
SCHEMBL20720018 0.87 MMP8 (0.61) CA12CA1CA2CA3CA4
SCHEMBL12505312 0.87 MMP8 (0.61) CA12CA1CA2CA3CA4
SCHEMBL7356728 0.86 CA12 (0.72) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118271200-A Industrial preparation method and application of lacosamide 北京澳合药物研究院有限公司 2024-07-02 CN claimed
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES PRIVATE LIMITED (IN) 2013-02-14 US claimed
EP-2534127-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN Laboratories Limited (IN) 2012-12-19 EP claimed
WO-2011130615-A2 PREPARATION OF LACOSAMIDE DR. REDDY'S LABORATORIES LTD. (IN) 2011-10-20 WO claimed
WO-2011099033-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES LIMITED (IN) 2011-08-18 WO claimed
CN-118271200-A Industrial preparation method and application of lacosamide 北京澳合药物研究院有限公司 2024-07-02 CN disclosed
CN-112745242-A Lacosamide impurity and preparation and application thereof 浙江华海药业股份有限公司 2021-05-04 CN disclosed
CN-111269140-A Preparation method of lacosamide 上海奥博生物医药技术有限公司 2020-06-12 CN disclosed
CN-106811492-B A kind of preparation method of scheme for lacosamide Changxing Pharmaceutical Co.,Ltd. (CN) 2019-11-01 CN disclosed
EP-3144295-B1 PROCESS FOR THE PREPARATION OF LACOSAMIDE DIVIS LABORATORIES LTD (IN) 2018-12-05 EP disclosed
EP-3144295-A1 PROCESS FOR THE PREPARATION OF LACOSAMIDE Divi's Laboratories Limited (IN) 2017-03-22 EP disclosed
EP-3144295-A1 PROCESS FOR THE PREPARATION OF LACOSAMIDE Divi's Laboratories Limited (IN) 2017-03-22 EP disclosed
EP-2534127-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN Laboratories Limited (IN) 2012-12-19 EP disclosed
EP-2444390-A1 Process for producing Lacosamide Archimica GmbH (DE) 2012-04-25 EP disclosed
US-20120095251-A1 Process for Producing Lacosamide EUTICALS GMBH (DE) 2012-04-19 US disclosed
WO-2011144983-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF LACOSAMIDE AUROBINDO PHARMA LIMITED (IN) 2011-11-24 WO disclosed
WO-2011130615-A2 PREPARATION OF LACOSAMIDE DR. REDDY'S LABORATORIES LTD. (IN) 2011-10-20 WO disclosed
WO-2011099033-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES LIMITED (IN) 2011-08-18 WO disclosed
WO-2011092559-A1 PROCESS FOR THE SYNTHESIS OF LACOSAMIDE ARCHIMICA SRL (IT) 2011-08-04 WO disclosed
EP-0996435-B1 AMINO ACID DERIVATIVES USEFUL TO TREAT STROKE RES CORP TECHNOLOGIES INC (US) 2002-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095251-A1 Process for Producing Lacosamide NAAA, TET3, GNMT CA12 168/4885CA1 126/4885CA2 53/4885
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE AMY1A, PTMA, NAAA CA12 3088/4885CA1 1930/4885CA2 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.